ARTEMIDE-Lung04 Trial
Phase 3
830
about 5.6 years
18+
31 sites in DE, FL, GA +14
What this study is about
Researchers are testing whether rilvegostomig or pembrolizumab monotherapy is effective as a first treatment for people with advanced non-small cell lung cancer whose tumors have high levels of PD-L1. The trial will last 2062 days and involve approximately 830 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Pembrolizumab
- 2.Receive Rilvegostomig
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Overall Survival (OS), Progression-Free Survival (PFS)
Secondary: Duration of Response (DoR), Landmark Overall Survival (OS) rates, Landmark Progression-Free Survival (PFS) rates, Objective Response Rate (ORR), Patient-reported global health status (GHS)/quality of life (QoL), Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Pharmakokinetics (PK) of rilvegostomig, Time to second progression or death (PFS2)
Oncology